Ebastine PCD Pharma Franchise Company
Cafoli Lifecare offers an Ebastine PCD pharma franchise built on 3 tablet formulations manufactured at WHO-GMP certified facilities. This gives franchise partners a modern non-sedating antihistamine line for physicians, ENT specialists and dermatologists.
What is Ebastine?
Ebastine is a second-generation, long-acting H1-antihistamine that selectively blocks peripheral histamine receptors with minimal sedation. It is used to relieve the symptoms of allergic rhinitis and chronic idiopathic urticaria. Read its profile on PubChem.
Therapeutic Applications
Ebastine is prescribed for seasonal and perennial allergic rhinitis and for chronic urticaria, often combined with montelukast for allergic airway disease. Its once-daily, non-drowsy profile suits patients who need to stay alert. Prescribers include general physicians, ENT surgeons, dermatologists and paediatricians.
Why Ebastine is a High-Potential Molecule for Distributors
Allergic rhinitis and urticaria affect a very large share of the population and recur seasonally, driving high-volume, repeat antihistamine sales. Ebastine differentiates itself within a crowded category through its long duration and low sedation, and montelukast combinations extend its value into respiratory-allergy prescribing. For a distributor, it is a high-turnover molecule with strong OTC-adjacent pull.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Ebastine
- PubMed: Ebastine literature
Our formulations of Ebastine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: